March 13, 2018
CUREWIZE, SUCCESSFULY COMPLETED CLINICAL TRIAL ON LAB TEST
Yokneam, Israel – Curewize, Curewize Successfully Completed Clinical Trial on Lab Test Revealing Acute Lymphoblastic Leukemia Patients’ Optimal Treatment Regimen .
November 21, 2016
CUREWIZE, TO PARTICIPATE AND PRESENT RESULTS AT 58TH ASH ANNUAL MEETING & EXPOSITION
Yokneam, Israel – Curewize, today announced that they will be presenting Results at 58th ASH Annual Meeting & Exposition, September 3
Curewize’s is Developing Technology based on findings published in Genes Chromosomes & Cancer (2016) showing microRNA expression in bone marrow sample taken at diagnosis can predict Pediatric Acute Lymphoblastic Leukemia patients risk for relapse.
November 17, 2016
BIOSHAI, WORLD'S FIRST BLOOD TEST TO AID DIAGNOSIS OF PARKINSON'S
Yokneam, Israel – Bioshai, expects to begin commercializing its unique assay in 2019, applying for CE clearance in Europe. You can read more about it in BIOSHAI’S article published in Israel21c
August 29, 2016
GLAUCOPHARM, N2B AND BIOSHAI TO PARTICIPATE AT SACHS ASSOCIATES 16TH ANNUAL BIOTECH IN EUROPE FORUM
Yokneam, Israel – Youdim Pharmaceuticals’ subsidiaries, GlaucoPharm, N2B and Bioshai, today announced that they will be presenting at the Sachs Associates convention for partnering and investment, September 27th – 28th, 2016, Congress Center Basel, Switzerland.
August 26, 2016
GLAUCOPHARM GAINS THIRD YEAR GOVERMENTAL FUNDING FROM OCS
Yokneam, Israel – GlaucoPharm, a pharmaceutical R&D company developing a proprietary compound, TG-46, for the treatment of glaucoma, has been granted a third year research budget by the OCS – Office of the Chief Scientist of Israel (Reshut Hachadshanut).
August 16, 2016
YOUDIM PHARMACEUTICALS TO PRESENT AT LIFE SCIENCES BALTICS, SEPTEMBER 2016, VILNIUS, LITHUANIA
Yokneam, Israel – Youdim Pharmaceuticals today announced that it will be presenting at the Life Sciences Baltics forum, September 14-15, 2016, Lithuanian Exhibition and Congress Center LITEXPO, Vilnius, Lithuania. The company’s management is set to meet Lithuanian government officials to discuss partnering and cooperation.
August 15, 2016
N2B APPOINTS NEW RESEARCH LEADER
Yokneam, Israel – N2B Ltd. announced today the recruitment of Dr. Hadile Ounallah-Saad, who did post – doctoral training at Haifa University (Eshkol Laurate) with a specialty in Alzheimer’s disease, to lead its research. N2B is a pharmaceutical drug repositioning company developing medical care for depression associated with early Parkinson’s disease (PD), through the proprietary reformulation of existing drugs.
August 1, 2016
YOUDIM PHARMACEUTICALS APPOINTS NEW IP STRATEGY DIRECTOR
Yokneam, Israel, August 1, 2016 – Youdim Pharmaceuticals named as its Intellectual Property Strategy Director Israeli patent attorney and US patent agent Avraham Hermon. Hermon is an expert in creating patent portfolios and IP strategy for pharmaceutical and biotech companies, and former Senior Manager at Teva’s Global Patent Group.
April 20, 2016
BIOSHAI LTD. TO PRESENT AT IATI BIOMED 2016 CONFERENCE IN MAY
Yokneam, Israel, April 20, 2016 – Bioshai Ltd., an emerging diagnostic company focused on the development of diagnostic biomarker kits for Parkinson’s disease, announced today that it has been chosen to display its achievements at Israel’s Biomed conference in May 2016.
April 14, 2016
CUREWIZE LTD. TO PRESENT AT IATI BIOMED 2016 CONFERENCE IN MAY
Yokneam, Israel, April 14, 2016 – Curewize Ltd., a clinical research and commercialization company aiming to advance the personalized treatment of cancers common to children, adolescents and young adults, announced today that it will provide an overview of its work at Israel’s Biomed conference in May 2016.
April 1, 2016
YOUDIM PHARMACEUTICALS MAKES CEO CHANGE AND RESTRUCTURES BOARD OF DIRECTORS
Yokneam, Israel, April 1, 2016 – Youdim Pharmaceuticals. Prof. Eliahu Heldman, co-founder of NeuroDerm (Nasdaq: NDRM), shall join the company’s Board of Directors and become a member of its Scientific Advisory Board.